Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16772 studies found for:    Open Studies | "Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Conditions: Neuroendocrine Neoplasms;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
Intervention:
2 Not yet recruiting Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract
Interventions: Drug: Lenvatinib;   Drug: Capecitabine
3 Recruiting Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
Intervention: Drug: Mithramycin
4 Unknown  Questionnaire Study for Gynecological Cancer Survivors
Conditions: Endometrial Neoplasms;   Ovarian Neoplasms;   Uterine Cervical Neoplasms;   Vulvar Neoplasms;   Vaginal Neoplasms;   Genital Neoplasms, Female
Intervention: Behavioral: Psychosocial
5 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
6 Recruiting Tumor Bank for Blood Samples
Conditions: Ovarian Neoplasms;   Breast Neoplasms;   Colorectal Neoplasms;   Neoplasms of the Female Genitalia;   Lung Neoplasms;   Endocrine Gland Neoplasms
Intervention: Other: Blood collection
7 Recruiting Tumor Bank for Tissue Samples
Conditions: Ovarian Neoplasms;   Breast Neoplasms;   Colorectal Neoplasms;   Neoplasms of the Female Genitalia;   Lung Neoplasms;   Endocrine Gland Neoplasms
Interventions: Other: Tumor tissue collection;   Other: Sampling of ascites and pleural effusion;   Other: Collecting urine samples;   Other: Collecting saliva sample;   Other: Collecting sputum;   Other: Collecting stool samples;   Other: Lavage/Irrigation
8 Recruiting Tumor Hypoxia With HX4 PET in Several Diseases
Conditions: Prostatic Neoplasms;   Esophageal Neoplasms;   Neoplasm Metastases, Brain;   Rectal Neoplasms;   Brain Neoplasm, Primary
Intervention: Drug: Injection with the hypoxia tracer [18F]HX4,
9 Not yet recruiting MED-C Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Conditions: Neoplasms;   Lung Neoplasms;   Colon Neoplasms;   Breast Neoplasms;   Pancreatic Neoplasms;   Prostate Neoplasms;   Kidney Neoplasms;   Liver Neoplasms;   Rectal Neoplasms;   Hematologic Neoplasms;   Multiple Myeloma;   Myelodysplastic Syndromes;   Ovarian Neoplasms;   Bladder Neoplasms;   Testicular Neoplasms;   Endometrial Neoplasms;   Brain Neoplasms;   Biliary Tract Neoplasms;   Head and Neck Neoplasms;   Uterine Cervical Neoplasms;   Skin Neoplasms;   Melanoma;   Gastric Neoplasms;   Anal Neoplasms;   Sarcoma
Intervention: Other: Provider determined
10 Recruiting A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Conditions: Sexual Dysfunctions, Psychological;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Uterine Neoplasms;   Genital Neoplasms, Female
Intervention: Behavioral: GyneGals Support Group
11 Recruiting Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
Conditions: Pancreatic Neoplasms;   Hepatocellular Cancer;   Cholangiocarcinoma;   Colorectal Neoplasms
Intervention: Drug: OXY111A
12 Not yet recruiting Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Conditions: Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs
Interventions: Drug: Alisertib;   Drug: TAK-228
13 Recruiting Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Conditions: Colorectal Neoplasms;   Neoplasm Metastases;   Hepatic Neoplasms
Intervention: Other: Diffusion Weighted MRI scan
14 Recruiting A Study of LY2880070 in Patients With Advanced or Metastatic Cancer
Conditions: Solid Tumors;   Colorectal Cancer;   Breast Cancer;   Ovarian Cancer;   Colon Cancer;   Rectal Cancer;   Neoplasms
Interventions: Drug: LY2880070;   Drug: Gemcitabine
15 Recruiting Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Carcinoma;   Malignant Neoplasm of Breast;   Cancer of Breast;   Mammary Neoplasm, Human;   Human Mammary Carcinoma;   Malignant Tumor of Breast;   Mammary Cancer;   Mammary Carcinoma;   Anxiety;   Fear;   Neoplasm Remission, Spontaneous;   Spontaneous Neoplasm Regression;   Regression, Spontaneous Neoplasm;   Remission, Spontaneous Neoplasm;   Spontaneous Neoplasm Remission
Interventions: Behavioral: Acceptance and Commitment Therapy;   Behavioral: Survivorship Education;   Behavioral: Usual Care
16 Recruiting Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
Conditions: Breast Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Interventions: Drug: Propofol;   Drug: Sevoflurane
17 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
18 Recruiting Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Conditions: Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Digestive System Neoplasms;   Endocrine Gland Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Lung Diseases;   Breast Neoplasms;   Breast Diseases;   Renal Neoplasm;   Solid Tumors
Interventions: Drug: Entinostat;   Other: Placebo
19 Recruiting Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Conditions: Neoplasms,;   Breast Neoplasms,;   Kidney Neoplasms,;   Pancreatic Neuroendocine Neoplasms
Interventions: Drug: alpelisib;   Drug: everolimus;   Drug: exemestane
20 Unknown  Early Detection of Cancers in Low Resource Countries
Conditions: Breast Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Endometrial Neoplasms
Interventions: Procedure: Breast Cancer Screening and Diagnosis;   Procedure: Cervical Cancer Screening and Diagnosis;   Procedure: Ovarian Cancer Screening and Diagnosis;   Procedure: Endometrial Cancer Screening and Diagnosis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years